Novozymes Balance Sheet Health
Financial Health criteria checks 5/6
Novozymes has a total shareholder equity of €10.9B and total debt of €3.0B, which brings its debt-to-equity ratio to 27.6%. Its total assets and total liabilities are €16.5B and €5.6B respectively. Novozymes's EBIT is €959.3M making its interest coverage ratio 26.2. It has cash and short-term investments of €327.2M.
Key information
27.64%
Debt to equity ratio
€3.02b
Debt
| Interest coverage ratio | 26.2x |
| Cash | €327.20m |
| Equity | €10.92b |
| Total liabilities | €5.60b |
| Total assets | €16.52b |
Recent financial health updates
Recent updates
NSIS B: Consumer Health Probiotics Expansion Will Support Higher Multiple Potential
The analyst fair value estimate for Novozymes has increased from DKK 520 to DKK 540, as analysts cite a series of higher Street price targets in the DKK 460 to DKK 552 range and improving views on the company following recent rating upgrades. Analyst Commentary on Novozymes Recent research on Novozymes, through the merged Novonesis entity, points to a more constructive tone from several bullish analysts.NSIS B: Consumer Ingredients And Probiotics Expansion Will Support Higher Multiple Potential
The analyst price target for Novozymes has been reset to DKK 520, with analysts pointing to updated assumptions on growth, profitability and valuation multiples as the main drivers of the change. Analyst Commentary Recent Street research on Novozymes, now part of Novonesis, shows a series of constructive shifts in sentiment, with several firms revisiting their assumptions on valuation, execution and growth.
NSIS B: Fair Outlook Will Rely On Probiotic Expansion In China
The analyst fair value estimate for Novozymes has been raised from DKK 380 to DKK 400, reflecting a series of higher Street price targets from multiple firms as analysts point to updated views on growth, margins and valuation for Novonesis. Analyst Commentary Recent Street research on Novozymes and Novonesis highlights a mix of optimism on long term potential and caution around execution and valuation risk.NSIS B: Consumer Ingredients And Probiotics Expansion Will Support Premium Multiple
Analysts have nudged the fair value estimate for Novozymes (Novonesis) slightly lower to DKK 548.58 from about DKK 560, reflecting a blend of trimmed Street price targets around DKK 552 and DKK 460, as well as updated assumptions for revenue growth, profit margins and a more conservative future P/E of 34x. Analyst Commentary Recent Street research on Novozymes reflects a mix of fine tuning on price targets and ratings, with bullish analysts focusing on the company’s positioning in consumer ingredients and its ability to support premium valuation metrics.Novozymes (CPSE:NSIS B) Stock Could Be 31% Below Fair Value After UndoAge Deal
UndoAge partnership puts Novozymes (CPSE:NSIS B) in focus The new Memorandum of Understanding between UndoAge and Novonesis to co develop probiotics and postbiotics for the Chinese consumer health market puts fresh attention on Novozymes stock for investors tracking microbiome related opportunities. See our latest analysis for Novozymes. At a share price of DKK394.2, Novozymes has seen momentum build recently, with a 30 day share price return of 5.40% and a 90 day gain of 12.44%, even as the...Financial Position Analysis
Short Term Liabilities: NSIS B's short term assets (€2.0B) exceed its short term liabilities (€1.2B).
Long Term Liabilities: NSIS B's short term assets (€2.0B) do not cover its long term liabilities (€4.4B).
Debt to Equity History and Analysis
Debt Level: NSIS B's net debt to equity ratio (24.6%) is considered satisfactory.
Reducing Debt: NSIS B's debt to equity ratio has reduced from 55.1% to 27.6% over the past 5 years.
Debt Coverage: NSIS B's debt is well covered by operating cash flow (42.5%).
Interest Coverage: NSIS B's interest payments on its debt are well covered by EBIT (26.2x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/17 08:09 |
| End of Day Share Price | 2026/08/14 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novozymes A/S is covered by 28 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Cezara Lozneanu | Barclays |
| Alexander Sloane | Barclays |
| Sebastian Satz | Barclays |